Table 1. Group age 1954 Rongelap <10 10-18 ‘>18 Total . Summary of thyroid abnormalities in the Marshallese, 1981. (Corrected = matched control value subtracted.)* Est. thy. Total nodules No. dose, rad No. * 22 12 33. 67 17 3 3 23 810-1150T 335- 810 335 556 av. Correc— Carcinoma ted 4 No. 4 77.3 25.0 9.1 34.3 74.7 17.4 1.2 28.5 1 1 2 4 4.5 8.3 6.1 6.0 2 28.6 26.0 & 6 36.4 31.6 28.5 35.8 Correc- ted 4 3.6 8.3 5.4 5.2 Ailingnae <10 7 10-18 1 >18 ll Total 19 275-450 190 135 217 av. Rong. + Ail. <10 29° 10-18 13. >18 44 Total 86 275-1150 190- 810 135- 335 482 av. 19 3 7 29 65.5 23.1 15.9 «(33.7 62.8 15.5 8.0 27.9 1 1 2 4 3.4 7.7 4.5 4.7 2.5 7.7 3.8 4.0 60-95 30-60 =630 51 av. 5 3 9 17 4.7 14.2 11.4 9.1 5.2 6.7 3.5 4.6 1 1 1 3 1.6 4.8 1.3 1.8 0.7 4.8 0.6 1.1 2 1 2 5 0.9 1.3 0.7 0.8 Utirik <10 10-18 >18 Total 64 21 79 164 Hypofunction** Correc- No. % ted % 3 13.6 13.6 4 7 11.8 10.4 11.9 10.1 Total lesions Correc- ted % 88.0 17.4 13.2 38.7 26.0 1 1 9.0 5.2 8.8 5.0 37.3. 30.8 3 10.3 10.3 5 8 11.4 9.3 11.1 9.0 73.1 15.5 19.1 36.9 5.2 6.7 3.5 4.6 Matched controls, unexposed <10 10-18 >18 Total 229 79 292 600 6 6 23 35 2.6 7.6 7.9 5.8 1 1 2 1.3 0.3 0.3 2.6tTT 8.9 8.2 6.2 *The cancer estimates are possibly underestimated since all unoperated nodules were considered benign for these calculations. Occult carcinomas were not included under carcinoma. **No nodule cases with hypofunction are included. (See Tables 1 and 2, Appendix IV.) fThe lower dose estimates for the <10 group were used for in utero cases. TTtNo correction necessary. ‘“ cm 9006 4 awd - 59 -